Passage Bio, Inc. PASG

PASG Company Overview

Passage Bio, Inc. is a clinical-stage genetic medicines company focused on developing adeno-associated virus (AAV)-based gene therapies for rare, monogenic central nervous system (CNS) disorders. The company operates within the biotechnology and gene therapy industries, with research and development centered on inherited neurodegenerative and neurodevelopmental diseases that currently have limited or no approved disease-modifying treatments. Its primary value drivers are its clinical and preclinical gene therapy programs, intellectual property related to CNS-targeted AAV delivery, and collaborations with leading academic research institutions.

The company was founded in 2017 and is headquartered in Philadelphia, Pennsylvania. Passage Bio was established through a strategic partnership with the University of Pennsylvania’s Gene Therapy Program, leveraging research developed by pioneers in AAV-based genetic medicine. The company completed its initial public offering in 2020 and has since focused on advancing therapies for diseases such as frontotemporal dementia (FTD) associated with progranulin deficiency and other rare neurological conditions. Its positioning is supported by access to translational research expertise, established manufacturing relationships, and a focus on orphan CNS indications where regulatory incentives and high unmet need may support development opportunities.